Area of research
Immunology · Nephrology
Research interest
Research focused on Eculizumab and Thrombotic microangiopathy, with related work in ADAMTS13, Exacerbation, Atypical hemolytic uremic syndrome. Notable publications include 'Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial', 'Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study', and 'The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment'.
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
Urine Metabolite Levels, Adverse Kidney Outcomes, and Mortality in CKD Patients: A Metabolome-wide Association Study
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP
Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study
Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
CKD273 Enables Efficient Prediction of Diabetic Nephropathy in Nonalbuminuric Patients
Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilate—Free Radical Scavenger and Growth Factor Inhibition
MP393LONG-TERM SAFETY AND EFFECTIVENESS OF ECULIZUMAB FOR PATIENTS WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME: OUTCOMES FROM A PROSPECTIVE OBSERVATIONAL CLINICAL TRIAL
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial
Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
Monocyte chemoattractant protein-1 and the kidney
Renal PKC-ε deficiency attenuates acute kidney injury and ischemic allograft injury via TNF-α-dependent inhibition of apoptosis and inflammation
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study
Microparticle generation and leucocyte death in Shiga toxin-mediated HUS